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DNA vaccines are usually given by intramuscular injection or by gene gun delivery of DNA-coated particles
into the epidermis. Induction of mucosal immunity by targeting DNA vaccines to mucosal surfaces may offer
advantages, and an oral vaccine could be effective for controlling infections of the gut mucosa. In a murine
model, we obtained protective immune responses after oral immunization with a rotavirus VP6 DNA vaccine
encapsulated in poly(lactide-coglycolide) (PLG) microparticles. One dose of vaccine given to BALB/c mice
elicited both rotavirus-specific serum antibodies and intestinal immunoglobulin A (IgA). After challenge at 12
weeks postimmunization with homologous rotavirus, fecal rotavirus antigen was significantly reduced com-
pared with controls. Earlier and higher fecal rotavirus-specific IgA responses were noted during the peak
period of viral shedding, suggesting that protection was due to specific mucosal immune responses. The results
that we obtained with PLG-encapsulated rotavirus VP6 DNA are the first to demonstrate protection against an
infectious agent elicited after oral administration of a DNA vaccine.
Group A rotavirus infections cause an estimated 870,000
deaths each year in developing countries (12). They also cause
55,000 to 70,000 hospitalizations per year in the United States,
with an estimated cost of more than $1 billion (12). Because of
the widespread nature of rotavirus disease, development of
vaccines is considered key to their control (1, 12). Although
progress has been made in the development of live oral rota-
virus vaccines (32), improved vaccines are still needed, partic-
ularly in many developing countries where the need is the
greatest (1, 12, 22, 33) but where the live oral vaccines have
been less effective (25, 26). Development of killed rotavirus
vaccines and subunit vaccines may be possible (1), but these
types of vaccines do not provide endogenously synthesized
proteins and generally do not elicit cytotoxic T-lymphocyte
(CTL) responses (13) that may be important in controlling
rotavirus infection. The use of DNA encoding specific viral
proteins allows for the expression of immunizing proteins by
host cells that take up inoculated DNA. This results in the
presentation of normally processed proteins to the immune
system, which is important for raising immune responses
against the native forms of proteins (11, 36). Expression of
the immunogen in host cells also results in the immunogen
having access to class I major histocompatibility complex
presentation, which is necessary for eliciting CD81 CTL
responses.
Rotavirus virions have a three-layered protein capsid. The
protein-coated RNA core is coated by VP6, a protein that is
antigenically conserved among group A rotaviruses but does
not elicit antibodies that neutralize rotavirus in vitro. The two
outer capsid surface proteins, VP4 and VP7, elicit neutralizing
antibodies. In prior studies, we found that DNA vaccines en-
coding VP4, VP7, or VP6 were protective when administered
by gene gun delivery of the DNA to the epidermis (3, 15, 16).
Direct gene gun inoculation to the anal mucosa required five-
fold less DNA (0.5 rather than 2.5 mg per mouse) to give the
same level of protection (17), suggesting that targeting muco-
sal tissue enhances the generation of protective immunity.
Both inoculation routes resulted in enhanced intestinal immu-
noglobulin A (IgA) responses after rotavirus challenge, but
neither induced detectable intestinal IgA prior to challenge.
Protective immune responses against rotavirus infections have
been correlated with production of rotavirus-specific fecal IgA
in vivo in human and porcine studies as well as in the murine
model (4, 10, 27, 34, 38). Thus, induction of intestinal IgA may
be an important correlate in the development of rotavirus
vaccines.
Targeting of rotaviruses to the gut-associated lymphoid tis-
sue by oral administration of an aqueous-based system of mi-
croencapsulated noninfectious rotaviruses generated serum
IgG and intestinal IgA antibody responses (24). This finding
suggests that mucosal targeting of DNAs expressing rotavirus
proteins might also generate immune responses. Recently, a
method for encapsulation of plasmid DNA which permits the
DNA to be orally administered has been developed. Plasmid
DNA encoding insect luciferase was encapsulated in poly(lac-
tide-coglycolide) (PLG) microparticles and oral administration
of these PLG microparticles stimulated serum IgG, IgM, and
IgA antibodies to luciferase (21). Luciferase-specific IgA was
also detected in stool samples, indicating a mucosal response.
In this study, we examined the ability of a PLG-encapsulated
rotavirus VP6 DNA vaccine to induce serum and mucosal
antibody responses and to protect against rotavirus infection
after challenge of adult mice.
* Corresponding author. Mailing address: Division of Infectious
Diseases, University of Massachusetts Medical School, 55 Lake Ave.
North, Worcester, MA 01655. Phone: (508) 856-2155. Fax: (508) 856-
5981. E-mail: John.E.Herrmann@banyan.ummed.edu.
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MATERIALS AND METHODS
Virus and mice. Epizootic diarrhea of infant mice (EDIM) rotavirus strain EW
(P10[16], G3) was used for preparation of cDNA encoding VP6 and for virus
challenge of mice. The virus challenge stock was prepared by passaging virus
from intestinal homogenates of EDIM rotavirus-infected infant mice in adult
mice. Virus for challenge was a stool sample diluted in saline. The 50% infective
dose (ID50) of the stock virus was the 50% shedding dose as determined by
detection of rotavirus antigen shed in feces of infected mice. The mice used for
vaccine studies were obtained from rotavirus-free colonies (Charles River Lab-
oratories, Portage, Mich.) at 6 to 8 weeks of age and were housed in plastic
microisolater cages before and after immunization. The model developed by
Ward et al. for BALB/c mice (35) was used to measure protective immunity. In
this model, the endpoint is infection rather than illness, because illness is gen-
erally limited to infant mice aged 15 days or younger. The adult mouse (6 weeks
or older) becomes infected and sheds virus in feces for approximately 1 week
postinfection. Protection after virus challenge was defined as significant reduc-
tion in rotavirus antigen shedding in feces.
Encapsulated DNA vaccine. The plasmid encoding rotavirus VP6 DNA (Fig.
1) was prepared by insertion of murine rotavirus VP6 cDNA into the pCMV
intron A TPA expression vector provided by J. Mullins, University of Washing-
ton (plasmid JW4303) (37). This vector uses sequences from the cytomegalovirus
(CMV) immediate-early promoter to drive transcription and sequences from
bovine growth hormone genes to provide polyadenylation signals. To prepare
VP6 DNA vaccine by cohesive end ligation, the TPA leader sequence was
removed by treatment with restriction endonucleases HindIII and BamHI. The
HindIII site was changed to a BamHI site, and the gene for VP6 (GenBank
accession no. U36474) was inserted as a BamHI-BamHI fragment. The gene had
been inserted in the BamHI site of plasmid Bluescript KS2 and was released by
BamHI digestion prior to insertion into plasmid JW4303. Newly constructed
plasmids in the correct orientation were identified by restriction endonuclease
digestion. Expression of rotavirus VP6 in transfected COS cells was confirmed by
indirect immunofluorescent staining with monoclonal antibody to VP6. The
monoclonal antibody had been prepared against a rotavirus SA-11 strain (5). The
control DNA vaccine was the plasmid without the viral cDNA insert.
Plasmid DNA was encapsulated in PLG microparticles by the solvent extrac-
tion technique as previously described (20, 21). In brief, the DNA was emulsified
with PLG dissolved in dichloromethane, and this water-in-oil emulsion was
emulsified with aqueous polyvinyl alcohol (an emulsion stabilizer) to form a
(water-in-oil)-in-water double emulsion. This double emulsion was added to a
large quantity of water to dissipate the dichloromethane, which resulted in the
microdroplets hardening to form microparticles. These were harvested by cen-
trifugation, washed several times to remove the polyvinyl alcohol and residual
solvent, and finally lyophilized. The microparticles containing DNA had a mean
diameter of 0.5 mm. To test for DNA content, the microparticles were dissolved
in 0.1 M NaOH at 100°C for 10 min. The A260 was measured, and DNA was
calculated from a standard curve. Incorporation of DNA into microparticles was
1.76 to 2.7 mg of DNA per mg of PLG for the VP6 DNA vaccine and 1.75 to 3.61
mg per mg of PLG for the plasmid control.
Immunization of mice. Three groups of BALB/c mice were inoculated orally
(by gavage) with PLG-encapsulated plasmid DNA encoding murine rotavirus
VP6 (n 5 13 mice total) or control plasmid DNA (n 5 10 mice total). The
microparticles were suspended in a solution of 0.1 M sodium bicarbonate in
distilled water (pH 8.5) and given at 0.5 ml/mouse. The DNA dose administered
was approximately 50 mg per mouse.
Antigen and antibody testing. For monitoring viral antigen shedding in mouse
feces, we used a monoclonal antibody-based enzyme-linked immunosorbent as-
say (ELISA) in microtiter plates as previously described (14). For evaluating
serum antibody responses, an indirect ELISA for total antibody (IgG, IgM, and
IgA) (3, 10, 15, 16) was used with EDIM rotavirus-coated wells. Intestinal IgA
antibodies to EDIM virus were determined by use of IgA-specific peroxidase-
labeled antiglobulin in an indirect ELISA (3, 10, 15, 16). Five percent (wt/vol)
stool suspensions in 0.01 M phosphate-buffered saline (PBS; pH 7.1) were fur-
ther diluted 1:4 (final dilution of 1:80) and used for assays of fecal IgA.
Statistical analyses. Statistical analyses were performed using a nonparamet-
ric Wilcoxon two-sample test for ranked data and analysis of variance and the
Student-Newman-Keuls test for multiple comparison of the differences among
experimental groups.
RESULTS
Serum antibodies. Inoculated mice were examined for se-
rum antibodies (IgG, IgM, and IgA) every 2 weeks for 12
weeks. A single immunization was sufficient to elicit a serum
antibody response by 4 weeks after inoculation, with peak titers
being reached by 6 weeks (Fig. 2). Twofold dilutions were
tested starting at a 1:100 dilution.
Protection against rotavirus challenge. Mice were chal-
lenged with 100 ID50 of EDIM rotavirus at 12 weeks postim-
munization to determine if the immunizations had provided
protection. The challenge virus used was given by oral gavage.
Protection was assessed by testing for the reduction of rotavi-
rus antigen shedding in stools. Significant reductions (P ,
0.0002) in virus antigen shed were noted on days 2, 3, and 4
(Fig. 3).
Rotavirus-specific IgA in stools. Immunized mice were ex-
amined for intestinal rotavirus-specific IgA before virus chal-
lenge at 4, 6, 8, 10, and 12 weeks postimmunization. The results
of the tests for detection of rotavirus-specific IgA in stools are
shown in Fig. 4. Significant production of fecal IgA (P , 0.003)
was detected in the PLG-encapsulated VP6 DNA-vaccinated
animals at 6, 8, 10, and 12 weeks, suggesting that rotavirus
antigen was expressed and a mucosal antibody response had
been induced. In previous studies using gene gun delivery, we
did not detect rotavirus-specific IgA in the stools of DNA-
immunized animals until after they were challenged with live
rotavirus (3, 15, 16).
To determine if oral immunization also enhanced IgA re-
sponses after virus challenge, intestinal IgA was measured by
an IgA rotavirus-specific ELISA. The mice orally inoculated
with the PLG-VP6 DNA vaccine gave higher and earlier A492
values (P , 0.01) at 0, 1, 3, and 5 days postchallenge than mice
FIG. 1. Diagram of the pCMVIA vector and the virus cDNA insert. SV 40
Ori, simian virus 40 origin of replication; CMV Pro, CMV immediate-early
promoter, intron A (largest CMV intron); BGH, bovine growth hormone gene
(provides polyadenylation [pA] signals).
FIG. 2. Rotavirus-specific serum ELISA antibodies mice from BALB/c mice
that had been orally inoculated (by gavage) with PLG-encapsulated VP6 DNA
vaccine (n 5 13) or with PLG-encapsulated control plasmid DNA (n 5 10).
Serum was collected at the times indicated and tested by an ELISA for total
antibody (IgG, IgM, and IgA) every 2 weeks for 12 weeks. Results are expressed
as geometric mean titers 6 standard error.
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that had been orally inoculated with PLG-control plasmid
DNA (Fig. 5).
DISCUSSION
Our studies with PLG-encapsulated DNA vaccines pre-
sented here used VP6 DNA. We selected the VP6 DNA vac-
cine for these studies because of the broad implications a
VP6-based vaccine has for the prevention of rotavirus infec-
tions. VP6 is an antigenically conserved protein among all
group A rotaviruses of both animal and human origin. Thus,
serotype specificity may not be a problem with VP6-based
vaccines. The protection was not as complete as that we re-
ported previously with gene gun immunizations, where rotavi-
rus antigen was not detected in the stools of mice immunized
with VP6 DNA vaccine (3, 15, 16). This could be related to
vaccine dose. The dose of 50 mg per mouse used was based on
doses used for expression of other antigens and may not be
optimal for our system, and lower doses of VP6 DNA vaccine
given by gene gun also resulted in partial protection (17).
Dose-response studies will determine the optimal vaccine
dose. Compared with gene gun delivery used in our previous
studies (3, 15, 16), more DNA is required when encapsulated
and given orally (50 mg, compared with two doses of 2.5 mg
given by gene gun). Although it may also be possible to induce
immune responses by oral administration of naked DNA in a
saline solution, encapsulated material protects the DNA from
degradation by nucleases. Oral administration of naked DNA
encoding luciferase did induce immune responses, but PLG
encapsulation enhanced the responses (22). We expect to com-
pare naked DNA with encapsulated DNA in future experi-
ments.
Protective immunity was measured by reduction of rotavirus
antigen shed after challenge, because adult mice (mice older
than 2 weeks) do not develop diarrhea following rotavirus
infection. However, as pointed out by others, protection from
rotavirus infection may be a more stringent measure of pro-
tection than protection from disease, because infection can
occur in the absence of disease (31). In studies with murine
rotaviruses given orally to mice, protection against rotavirus
challenge is associated with rotavirus-specific fecal IgA (10,
35). We have also found that fecal IgA antibodies were rapidly
induced in mice immunized with rotavirus DNA vaccines, but
only after they were virus challenged (3, 15, 16). We had
previously shown that VP6 DNA vaccine induced both serum
antibodies and CTL responses after gene gun immunization (3,
15, 16). The serum antibodies did not neutralize rotavirus in
vitro; thus, it is unlikely that traditional virus neutralization is
involved in the protection found.
The mechanism of protection seen with the VP6 DNA vac-
cine and also with VP6-based virus-like particles (31) are not
known. Among potential mechanisms of protection are cell-
mediated immunity and IgA-mediated intracellular neutraliza-
tion of virus that is undergoing assembly. In studies with rota-
virus VP 2, 6 virus-like particles (31), protective immunity was
obtained by coadministration of cholera toxin, which is known
FIG. 3. Protection against EDIM rotavirus challenge in BALB/c mice. Mice
were challenged with 100 ID50 of virus per mouse 12 weeks after receiving
PLG-encapsulated VP6 DNA vaccine (n 5 13) or PLG-encapsulated control
plasmid DNA (n 5 10) by oral gavage. Virus shedding in feces, determined by an
ELISA for detecting rotavirus antigen, is given as A492 6 standard deviation. A
positive test is one in which the A492 is $0.1. There were significant differences
(P , 0.0002) in viral shedding between the mice receiving the plasmid encoding
VP6 and the plasmid control on the days indicated by an asterisk.
FIG. 4. ELISA for rotavirus-specific IgA in stool suspensions from mice that
had been orally inoculated (by gavage) with PLG-encapsulated VP6 DNA vac-
cine (n 5 13) or with PLG-encapsulated control plasmid DNA (n 5 10). The
stools were diluted 1:80 (wt/vol) in PBS. Results are expressed as A492 6 stan-
dard deviation. Values of .0.1 are considered positive for IgA. There were
significant differences (P , 0.004) in fecal IgA values between the mice receiving
the plasmid encoding VP6 and the plasmid control on the days indicated by an
asterisk.
FIG. 5. ELISA for rotavirus-specific IgA in stool suspensions from mice that
had been orally inoculated (by gavage) with PLG-encapsulated VP6 DNA vac-
cine (n 5 13) or with PLG-encapsulated control plasmid DNA (n 5 10) and
challenged with EDIM rotavirus. The stools were diluted 1:80 (wt/vol) in PBS.
Results are expressed as A492 6 standard deviation. An A492 of .0.1 is consid-
ered positive for IgA. There were significant differences (P , 0.01) in fecal IgA
values between the mice receiving the plasmid encoding VP6 and the plasmid
control on the days indicated by an asterisk.
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to enhance both mucosal antibody responses and CTL re-
sponses, and it is possible that either or both types of immune
responses are involved. IgA-mediated intracellular virus neu-
tralization has been shown for Sendai virus and influenza virus
(28, 29), and studies with IgA monoclonal antibodies to VP6
suggest that IgA-mediated intracellular neutralization may
also occur with rotaviruses (2). Based on these findings and our
demonstration of enhanced IgA responses in VP6 DNA-vac-
cinated mice both before and after virus challenge, IgA-medi-
ated intracellular neutralization in the intestinal mucosa may
be a factor in the protective immunity that we have obtained.
We expect to test DNA vaccines in immunodeficient mice to
help determine the relative importance of CTL responses and
intestinal IgA in the protection obtained with VP6 DNA vac-
cines.
Determination of the cell or cells targeted by the encapsu-
lated DNA and the ultimate fate of the DNA was beyond the
scope of this study, but it is likely that the cells involved are
similar to those that have been shown to be involved in the
uptake of PLG microparticles. Following oral administration
to mice, PLG microparticles 1 to 10 mm in diameter were taken
up into the Peyer’s patches of the gut-associated lymphoid
tissue. Those particles $5 mm that were taken up remained
localized for up to 35 days, whereas those particles ,5 mm
were disseminated within macrophages, mesenteric lymph
nodes, blood circulation, and spleen (8, 9). PLG microparticles
are not selectively targeted to M cells, but nonspecific binding
to M cells and subsequent transcytosis has been shown in
rabbits (18, 19). PLG microparticles ,5 mm have also been
shown to cross the intestinal mucosa at the site of Peyer’s
patches in rats (6). The DNA-containing PLG microparticles
used in our study had a mean diameter of 0.5 mm. It has been
presumed that PLG microparticles containing antigen bind to
and are transported by M cells in a manner similar to that
found with empty PLG microparticles (30). Supporting this
assumption, uptake of bovine serum albumin encapsulated in
PLG microparticles by Peyer’s patches has been shown in a rat
model (7).
The use of DNA vaccines is a new approach to immuniza-
tion that may provide more effective rotavirus vaccines. It has
been suggested that this approach and the virus-like particle
approach may make a third generation of rotavirus vaccines
(33). DNA vaccines encapsulated in PLG microparticles com-
bine the advantages of DNA-based vaccination with the ease of
administration by the oral route and concomitant induction of
mucosal immune responses. The results that we obtained with
PLG-encapsulated rotavirus VP6 DNA are the first to demon-
strate protection against an infectious agent elicited after oral
administration of a DNA vaccine.
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